AnaptysBio, Inc. (NASDAQ:ANAB) had its price objective increased by analysts at Royal Bank Of Canada from $40.00 to $79.00 in a report issued on Tuesday. Royal Bank Of Canada’s target price suggests a potential upside of 12.20% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Credit Suisse Group lifted their price objective on shares of AnaptysBio from $38.00 to $85.00 in a research note on Tuesday. JMP Securities lifted their price objective on shares of AnaptysBio from $45.00 to $82.00 and gave the stock an “outperform” rating in a research note on Tuesday. Stifel Nicolaus reissued a “buy” rating and issued a $35.00 price objective on shares of AnaptysBio in a research note on Tuesday, September 12th. Zacks Investment Research raised shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research note on Wednesday, September 13th. Finally, Robert W. Baird started coverage on shares of AnaptysBio in a research note on Monday, July 10th. They issued an “outperform” rating and a $36.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, AnaptysBio currently has a consensus rating of “Buy” and an average price target of $54.43.

Shares of AnaptysBio (NASDAQ ANAB) traded up 101.17% on Tuesday, reaching $70.41. 5,824,148 shares of the company traded hands. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $70.48. The firm’s market capitalization is $1.43 billion. The stock has a 50-day moving average price of $34.23 and a 200 day moving average price of $34.23.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.29. The company had revenue of $7.00 million during the quarter, compared to the consensus estimate of $3.45 million. Analysts anticipate that AnaptysBio will post ($1.98) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/10/royal-bank-of-canada-raises-anaptysbio-inc-anab-price-target-to-79-00.html.

In related news, major shareholder Holdings A/S Novo sold 70,706 shares of AnaptysBio stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the completion of the transaction, the insider now directly owns 3,009,949 shares of the company’s stock, valued at approximately $70,161,911.19. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of AnaptysBio stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here. Insiders sold a total of 1,133,940 shares of company stock valued at $24,223,316 over the last three months.

Several hedge funds have recently added to or reduced their stakes in ANAB. Bank of America Corp DE purchased a new position in shares of AnaptysBio during the 1st quarter worth about $123,000. DAFNA Capital Management LLC boosted its stake in shares of AnaptysBio by 22.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 1,000 shares during the period. New York State Common Retirement Fund purchased a new position in shares of AnaptysBio during the 2nd quarter worth about $168,000. TIAA CREF Investment Management LLC purchased a new position in shares of AnaptysBio during the 1st quarter worth about $227,000. Finally, Teachers Advisors LLC boosted its stake in shares of AnaptysBio by 23.4% during the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 1,807 shares during the period. 71.35% of the stock is owned by hedge funds and other institutional investors.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.